

## **ARTICOLI PEER REVIEWED**

1. Sonzogni A, Colloredo G, Fabris L, Cadamuro M, Paris B, Roffi L, Pozzi M, Bovo G, Del Poggio P, Portmann BC, Strazzabosco M. Isolated idiopathic bile ductular hyperplasia in patients with persistently abnormal liver function tests. J Hepatol. 2004; 40: 592-598. **(IF: 12,486) (4,816)**
2. Fabris L, Cadamuro M, Fiorotto R, Roskams T, Spirli C, Melero S, Sonzogni A, Joplin RE, Okolicsanyi L, Strazzabosco M. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006; 43: 1001-1012. **(IF: 13,246) (10,446)**
3. Fabris L, Cadamuro M, Guido M, Spirli C, Fiorotto R, Colledan M, Torre G, Alberti D, Sonzogni A, Okolicsanyi L, Strazzabosco M. Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol. 2007;171:641-653. **(IF: 4,057) (5,487)**
4. Fiorotto R, Spirli C, Fabris L, Cadamuro M, Okolicsanyi L, Strazzabosco M. Ursodeoxicholic acid stimulates cholangiocytes fluid secretion in mice via CFTR-dependent secretion. Gastroenterology 2007;133:1603-1613. **(IF: 18,392) (11,673)**
5. Fabris L\*, Cadamuro M\*, Libbrecht L, Raynaud P, Spirli C, Fiorotto R, Okolicsanyi L, Lemaigre FP, Strazzabosco M, Roskams T. Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology 2008;47:719-728. **(IF: 13,246) (11,355) (\* primo nome condiviso)**
6. Fabris L, Cadamuro M, Okolicsanyi L. The patient presenting with isolated hyperbilirubinemia. Dig Liver Dis. 2009; 41:375-381. **(IF: 3,061) (2,972)**
7. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M. ERK1/2-Dependent Vascular Endothelial Growth Factor Signaling Sustains Cyst Growth in Polycystin-2 Defective Mice. Gastroenterology 2010; 138: 360-371. **(IF: 18,392) (11,637)**
8. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M. Mammalian target of Rapamycin regulates vascular endothelial growth factor-dependent liver cysts growth in Polycystin-2 defective mice. Hepatology 2010; 51: 1778-1788. **(IF: 13,246) (10,885)**
9. Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M, Pierantonelli M, Trozzi L, Bugianesi E, Guido M, Strazzabosco M, Benedetti A,

Marchesini G. Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. *Gut* 2010; 60: 108-115. **(IF: 16,658) (10,614)**

10. Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, Nardo G, Sonzogni A, Colledan M, Furlanetto A, Bassi N, Massani M, Cillo U, Mescoli C, Indraccolo S, Ruge M, Okolicsanyi L, Strazzabosco M. Nuclear expression of S100A4 calcium binding protein increases cholangiocarcinoma invasiveness and metastasization. *Hepatology* 2011; 54:890-899 **(IF: 13,246) (11,665)**
11. Colombo F, Porretti L, Baldan F, Mazzucchelli S, Gueneri S, Cadamuro M, Spreafico M, Foglieni B, Prati D. Evidence of clonal evolution of tumor initiating cells in human hepatocellular carcinoma. *PlosONE* 2011 6: e21369. **(IF: 2,806) (4,092)**
12. Cadamuro M, Nardo G, Indraccolo S, Dall'Olmo L, Sambado L, Moserle L, Franceschet I, Morton S, Colledan M, Massani M, Stecca T, Bassi N, Spirli C, Fiorotto R, Fabris L, Strazzabosco M. Platelet-Derived Growth Factor-D and Small Rho GTPases regulate Recruitment of Cancer-Associated Fibroblasts In Cholangiocarcinoma. *Hepatology* 2013; 58: 1042-1053. **(IF: 13,246) (11,19)**
13. Cadamuro M, Morton SD, Strazzabosco M, Fabris L. Unveiling the Role of Tumor Reactive Stroma in Cholangiocarcinoma: an Opportunity for New Therapeutic Strategies. *Transl Gastrointest Cancer* 2013; 2: 130-144.
14. Spirli C, Locatelli L, Morell CM, Fiorotto R, Morton SD, Cadamuro M, Fabris L, Strazzabosco M. PKA dependent p-Ser-<sup>675</sup>β-catenin, a novel signaling defect in a mouse model of Congenital Hepatic Fibrosis. *Hepatology*, 2013;58:1713-1723. **(IF: 13,246) (11,19)**
15. Massani M, Stecca T, Fabris L, Caratozzolo E, Ruffolo C, Furlanetto A, Morton S, Cadamuro M, Strazzabosco M, Bassi N. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. *Oncol Rep.* 2013;30:1143-1148. **(IF: 2,662) (2,191)**

16. Morton SD\*, Cadamuro M\*, Brivio S, Stecca T, Vismara M, Massani M, Bassi N, Joplin RE, Floreani A, Strazzabosco M, Fabris L. Leukaemia Inhibitory Factor Protects Cholangiocarcinoma Cells from Drug-Induced Cytotoxicity via a PI3K-dependent Mcl-1 Activation. *Oncotarget* 2015;22;6:26052-26064. **(IF: 5,168) (5,008)** (\*primo nome condiviso).
17. Fabris L, Brivio S, Cadamuro M^, Strazzabosco M. Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the 'Reactive' Biliary Epithelial Phenotype. *Stem Cells Int.* 2016:2953727. **(IF: 3,540) (3,54)** (^corresponding author).
18. Cadamuro M^, Strazzabosco M, Fabris L. The multitasking behavior of cholangiocyte in the reaction to liver damage. *J Liver Clin Res.* 2: 1017. (^corresponding author).
19. Locatelli L\*, Cadamuro M\*, Spirli C, Fiorotto R, Lecchi S, Morell CM, Popov Y, Scirpo R, De Matteis M, Amenduni M, Pietrobattista A, Torre G, Schuppan D, Fabris L, Strazzabosco M. Macrophage recruitment by Fibrocystin-defective biliary epithelial cells promotes portal fibrosis in Congenital Hepatic Fibrosis. *Hepatology* 2016;63:965-982. **(IF: 13,246) (IF: 13,246)** (\*primo nome condiviso)
20. Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? *J Clin Med.* 2015;4:2028–2041.
21. Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Gaslini C, Stecca T, Massani M, Furlanetto A, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. *Cancer Res.* 2016;76:4775-4784. **(IF: 9,122) (9,122)**
22. Cadamuro M, Strazzabosco M, Fabris L. Personalized molecular targeted therapy for hepatocellular carcinoma in the era of genome sequencing. *Translational cancer research.* 2016;5:S420-S424. Editorial. **(IF: 1,167) (1,167)**
23. Fiorotto R, Villani A, Kourtidis A, Scirpo A, Amenduni M, Geibel PJ, Cadamuro M, Spirli C, Anastasiadis PZ, Strazzabosco M. CFTR controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. *Hepatology.* 2016;64:2118-2134 **(IF: 13,246) (IF: 13,246)**
24. Cilibrasi C, Riva G, Romano G, Cadamuro M, Bazzoni R, Butta V, Paoletta L, Dalprà L, Strazzabosco M, Lavitrano M, Giovannoni R, Bentivegna A. Resveratrol

- Inhibits Proliferation and Strongly Decreases Motility in Glioma Stem Cells, Modulating the Wnt Signaling Pathway. PlosONE, 2017; 12:e0169854 **(IF: 2,806) (2,806)**
25. Cadamuro M, Brivio S, Strazzabosco M, Fabris L. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci 2017; 18. pii: E149. **(IF: 3,226) (IF: 3,226)**
26. Brivio S, Cadamuro M, Strazzabosco M, Fabris L. The tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness. World Journal of Hepatology. 2017;9:455-468.
27. Fabris L, Spirli C, Cadamuro M, Fiorotto R, Strazzabosco M. Emerging Concepts in Biliary Repair and Fibrosis. Am J Physiol Gastrointest Liver Physiol. 2017;313:G102-G116. **(IF: 3,468) (IF: 3,468)**
28. Strazzabosco M, Fiorotto R, Cadamuro M, Spirli C, Mariotti V, Kaffe E, Scirpo R, Fabris L. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. BBA Molecular Basis of Disease, *in press*. **(IF: 5,476) (IF: 5,476)**
29. Bombelli S, Meregalli C, Scalia C, Bovo G, Torsello B, De Marco S, Cadamuro M, Viganò P, Strada G, Cattoretti G, Bianchi C, Perego RA. Nephrosphere-Derived Cells are Induced to Multilineage Differentiation when Cultured on Human Decellularized Kidney Scaffolds. Am J Pathol. 2018;188:184-195. **(IF: 4,057) (IF: 4,057)**
30. Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. BBA Molecular Basis of Disease, *in press*. **(IF: 5,476) (IF: 5,476)**
31. Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview. GE Liver, 2017. *In press*.
32. Morell CM, Fiorotto M, Meroni M, Raizner A, Torsello B, Cadamuro M, Sutti S, Albano E, Strazzabosco M. Notch signaling and progenitor/ductular reaction in steatohepatitis. PlosONE, 2017;12:e0187384. **(IF: 2,806) (2,806)**
33. Kaffe E, Fiorotto R, Pellegrino F, Mariotti V, Amenduni M, Cadamuro M, Fabris L, Strazzabosco M, Spirli C.  $\beta$ -catenin and IL-1 $\beta$  dependent CXCL10 production drives progression of disease in a mouse model of Congenital Hepatic Fibrosis. Hepatology, 2018;67:1903-1919. **(IF: 13,246) (IF: 13,246)**

34. Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular mechanisms driving Cholangiocarcinoma invasiveness: an overview. *Gene Expression* 2018. *In press*.
35. Romano G, Reggi S, Kutryb-Zajac B, Facoetti A, Chisci E, Pettinato M, Giuffrè MR, Vecchio F, Leoni S, De Giorgi M, Avezza F, Cadamuro M, Crippa L, Leone BE, Lavitrano M, Rivolta I, Barisani D, Smolenski RT, Giovannoni R. APOA-1<sup>Milano</sup> muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties *in vitro* and in *Apoe*<sup>-/-</sup> atherosclerotic mice. *IJC* 2018. *In press*. **(IF: 6,189) (IF: 6,189)**
36. Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. Animal models of Cholangiocarcinoma: what they teach us about the human disease. *Clin Res Hepatol Gastroenterol* 2018. *In press*. **(IF: 2,323) (IF: 2,323)**
37. Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L. Precision Medicine in Cholangiocarcinoma. *Transl Gastroenterol Hepatol*. *In press*.

## **CAPITOLI DI LIBRI**

- In: S. DeMorrow, M. Marzioni, G. Fava, S. Glaser, G. Alpini, eds. Pathophysiology of the Intrahepatic Biliary Epithelium. Kerala (India): Transworld Research Network, 2009: 21-35. C. Spirli, L. Fabris, R. Fiorotto, M. Cadamuro, S. Okolicsanyi, M. Strazzabosco. *Role of angiogenesis and angiogenic factors for cholangiocyte growth*. ISBN: 978-81-7895-337-3.
- In: Collana di Patologia Sistemica, Medica e Chirurgica, "Malattie dell'apparato gastrointestinale" L. Okolicsanyi, A. Peracchia, L. Roncoroni, eds. Milano: McGraw-Hill, 2008, 4a edizione. ISBN: 9788838639494.
  - a) L. Fabris, M. Cadamuro, L. Okolicsanyi, M. Strazzabosco. 37. *Colestasi intraepatica*: 367-380.
  - b) M. Cadamuro, L. Fabris, M. Strazzabosco. 38. *Colestasi Genetiche*: 381-388.
  - c) R.M. Iemmolo, L. Fabris, M. Cadamuro, M. Strazzabosco. 39. *Cirrosi Biliare Primitiva*: 389-396.
  - d) L. Okolicsanyi, M. Cadamuro, L. Fabris. 40. *Colangite Sclerosante Primitiva*: 397-404.
- In: Fibrocystic Diseases of the Liver. Edited by Murray K.F., MD, Larson A.M.,

MD. Human Press, Springer Science Business Media, LLC, Totowa, NJ, USA, 2010. S. Lecchi, L. Fabris, C. Spirli, M. Cadamuro, R. Fiorotto, M. Strazzabosco. *Cholangiocyte biology as relevant to cystic liver diseases*. ISBN 978-1-60327-524-8.

- In: Studies on Hepatic Disorders. Parola M, Albano E, eds. Springer Science Textbook; 2015. Cadamuro M, Fabris L, Strazzabosco M. 13. *Oxidative Stress in Non-Autoimmune Liver Diseases*: 309-324. ISBN 978-3-319-15539-5.
- In: Biliary Disease. Hirschfield G, eds. Springer Science Textbook; 2017, *in press*. Cadamuro M, Fabris L, Strazzabosco M. 2. *The healthy biliary tree - cellular and immune-biology*: 17-41. ISBN: 978-331950168-0;978-331950166-6